BROOKS vs COHANCE: Stock Comparison
Cohance Lifesciences Limited is the larger company by market capitalisation. Brooks Laboratories Limited shows a lower P/E, a higher ROE and faster revenue growth, while Cohance Lifesciences Limited shows a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BROOKS leads 10; COHANCE leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BROOKS | COHANCE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BROOKS | COHANCE |
|---|---|---|
| Live Price | ₹69.58 | ₹463 |
| Day Change | -3.45% | -2.64% |
| Volume | 91,999 | 16.39 L |
| 52-Week High | ₹163.9 | ₹1,038.9 |
| 52-Week Low | ₹36.3 | ₹266.7 |
| Distance from 52W High | -57.55% | -55.43% |
Valuation
| Metric | BROOKS | COHANCE |
|---|---|---|
| Market Cap | ₹182 Cr | ₹17,71,425.64 L Cr |
| P/E Ratio | 8.22x | 167.27x |
| P/B Ratio | 1.65x | 4.55x |
| EPS | ₹7.32 | ₹2.78 |
| Book Value | ₹33.3 | ₹102.03 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | BROOKS | COHANCE |
|---|---|---|
| Revenue Growth (TTM YoY) | -6.37% | -26.3% |
| EPS Growth (TTM YoY) | 0% | -89% |
| Qtr Sales Growth | 42.3% | -26.3% |
| Qtr Profit Growth | 498% | -86.6% |
Profitability & Leverage
| Metric | BROOKS | COHANCE |
|---|---|---|
| ROE | 20.04% | 7.04% |
| ROCE | -9.93% | 8.35% |
| Net Margin | 28.67% | 7.9% |
| Operating Margin | 7.74% | 18.8% |
| Debt to Equity | 0.06x | 0.1x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BROOKS | COHANCE |
|---|---|---|
| Promoter Holding | 52.62% | 0% |
| FII Holding | 0%▼ 0.17 pp | 6.5%▲ 0.91 pp |
| DII Holding | 10.38% | 20.09%▼ 1.7 pp |
| Public Holding | 37%▲ 0.16 pp | 15.92%▲ 0.8 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Brooks Laboratories Limited and Cohance Lifesciences Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.